Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMedOpen access

Identification of novel hub genes and pathways predictive of fibrosis progression in cancer-related lymphedema through integrated multi-omics.

Chen J., Chen Y., Wang L., Deng Y., Zhou Y., Wang Y.

Laboratory Study on Scar, published in Front Immunol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Front Immunol (2025)
Country
Switzerland
Reported sample size
—
Source database
PubMed
PMID
40881699
PMCID
PMC12380543
DOI
10.3389/fimmu.2025.1625972
Citations
1

Abstract (original English)

Background Cancer-related lymphedema (CRL) is a common chronic complication following cancer treatment, characterized by impaired lymphatic drainage, interstitial fluid retention, and progressive fibrosis. Although the mechanisms of hypertrophic scar (HTS) fibrosis have been extensively investigated, the molecular drivers of fibrosis in CRL remain unclear. Identification of reliable biomarkers and novel therapeutic targets is essential for enabling early intervention. Methods Transcriptomic datasets of CRL and HTS from the Gene Expression Omnibus (GEO) were integrated to identify fibrosis-associated differentially expressed genes (DEGs) and construct co-expression modules. Weighted gene co-expression network analysis (WGCNA) and protein-protein interaction (PPI) network analysis were employed to nominate hub genes. Single-cell RNA sequencing (scRNA-seq) data were used to localize candidate gene expression within immune and mesenchymal cell populations. The most promising biomarker was validated in clinical CRL tissues by Masson's trichrome staining and Western blotting, and Pearson correlation analyses were performed to assess its association with collagen deposition and disease duration. Results A total of 154 fibrosis-related genes were found to be shared by CRL and HTS. Among them, Asporin (ASPN) emerged as the most promising hub gene, with markedly elevated expression in la

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansFibrosisLymphedemaDisease ProgressionNeoplasmsProtein Interaction MapsGene Regulatory NetworksGene Expression ProfilingTranscriptomeComputational Biology

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research